scholarly journals Serum Cytokine Profiles Associated with Specific Adjuvants Used in a DNA Prime-Protein Boost Vaccination Strategy

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e74820 ◽  
Author(s):  
Rachel Buglione-Corbett ◽  
Kimberly Pouliot ◽  
Robyn Marty-Roix ◽  
Kim West ◽  
Shixia Wang ◽  
...  
2019 ◽  
Vol 51 (8) ◽  
pp. 2529-2538 ◽  
Author(s):  
Sagar A. Khulape ◽  
Hemanta Kumar Maity ◽  
Dinesh Chandra Pathak ◽  
Narayan Ramamurthy ◽  
Saravanan Ramakrishnan ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Yuan Gu ◽  
Bin Zhan ◽  
Yaping Yang ◽  
Xiaodi Yang ◽  
Xi Zhao ◽  
...  

Trichinellosis is a widespread zoonosis primarily caused byTrichinella spiralis. Mucosal immunity is crucial for preventingTrichinella spiralisinfection. In our previous study, a DNA vaccine with theTrichinellaantigen Ts87 delivered by an attenuatedSalmonella typhimuriumelicited partial protection againstTrichinella spiralisinfection in mice. In the current study, to elicit a more robust immune response and develop a potent vaccination strategy against trichinellosis, a heterologous prime-boost vaccination regimen for Ts87 was used in mice and the protective efficacy was evaluated compared to the homologous DNA prime-boost or protein prime-boost immunization alone. The results revealed that the DNA-prime/protein-boost vaccination with Ts87 induced higher levels of both humoral and cellular immune responses. The challenge results showed that mice with the DNA-prime/protein-boost vaccination displayed higher muscle larval reduction than those immunized with DNA prime-boost or protein prime-boost. The results demonstrated that mice vaccinated with Ts87 in a DNA-prime/protein-boost strategy effectively elicited a local IgA response and mixed Th1/Th2 immune response that might be responsible for improved protection againstTrichinella spiralisinfection.


2007 ◽  
Vol 66 (1) ◽  
pp. 43-51 ◽  
Author(s):  
K. Hallermalm ◽  
S. Johansson ◽  
A. Bråve ◽  
M. Ek ◽  
G. Engström ◽  
...  

2007 ◽  
Vol 13 (3) ◽  
pp. 284-289 ◽  
Author(s):  
Mark P Zanin ◽  
Diane E Webster ◽  
Steven L Wesselingh

Rheumatology ◽  
2020 ◽  
Author(s):  
Jyoti Ranjan Parida ◽  
Sandeep Kumar ◽  
Sakir Ahmed ◽  
Smriti Chaurasia ◽  
Ratnadeep Mukherjee ◽  
...  

Abstract Objectives Peripheral SpA (pSpA) is comprised of ReA, PsA, enteritis-associated arthritis and undifferentiated pSpA (upSpA). ReA and upSpA share T cell oligotypes and metabolomics in serum and SF. We investigated HLA-B27 subtypes and cytokines in serum and SF that were compared between ReA and upSpA. Methods ReA and upSpA were compared in two cohorts. In cohort I (44 ReA and 56 upSpA), HLA-B27 subtyping was carried out. In cohort II (17 ReA and 21 upSpA), serum and SF cytokines were compared using a multiplex cytokine bead assay (27 cytokines). A total of 28 healthy controls with similar age and sex to cohort II were included for comparison of serum cytokine levels. Results In cohort I, HLA-B27 was positive in 81.8% (36/44) of ReA and 85.71% (48/56) of upSpA patients. HLA-B27 typing was successful in 70 patients (30 ReA and 40 uSpA). HLA-B*2705 was the most common, followed by HLA-B*2704 and HLA-B*2707. Frequencies were the same between ReA and upSpA. In cohort II, 14 cytokines were detectable in the serum of patients. The levels of eight cytokines were higher than in the controls. The cytokine levels of ReA and upSpA were similar. Sixteen cytokines were detectable in the SF of patients. There was no statistical difference in the levels between ReA and upSpA. The cytokine profiles in sera and SF were also similar among HLA-B27-positive and negative patients. Conclusion ReA and upSpA have similar HLA-B27 subtype associations and similar cytokine profiles. They should be considered as a single entity during studies as well as clinical management.


Vaccine ◽  
1997 ◽  
Vol 15 (15) ◽  
pp. 1661-1669 ◽  
Author(s):  
David Davis ◽  
Bror Morein ◽  
Lennart Åkerblom ◽  
Karin Lövgren-Bengtsson ◽  
Mariëlle E. van Gils ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document